Form 4: Phathom CEO Basta's PSU Vesting & Tax Withholding

Phathom Pharmaceuticals CEO Steven L. Basta reported the vesting of 90,000 performance stock units and the subsequent disposition of shares for tax withholding.

Summary

• Steven L. Basta, President and CEO of Phathom Pharmaceuticals, Inc., reported transactions involving company stock.
• On September 25, 2025, 90,000 performance stock units (PSUs) vested due to the achievement of a stock price hurdle.
• These 90,000 PSUs converted into 90,000 shares of common stock.
• Concurrently, 48,375 shares were disposed of to satisfy tax withholding obligations at a price of $11.66 per share.
• Following these transactions, Basta directly owns 41,625 shares of common stock.
• Basta also holds 270,000 unvested performance stock units.

Sentiment

Score: 7

Explanation: The vesting of performance stock units due to a stock price hurdle is a positive indicator of company performance, as it signifies the achievement of a pre-defined target. The subsequent share disposition for tax purposes is a neutral, routine event that does not reflect negatively on the company's outlook.

Positives

• 90,000 performance stock units vested, indicating the achievement of a pre-defined stock price hurdle.
• The vesting demonstrates that the company's stock performance met a specific target, aligning executive incentives with shareholder value.

Negatives

• 48,375 shares were disposed of to cover tax withholding obligations, reducing Steven L. Basta's direct common stock ownership.

Future Outlook

The remaining 270,000 performance stock units held by Steven L. Basta are subject to vesting based on the achievement of future stock price hurdles over a period of four years following the grant date, contingent on his continued service through the date each such stock price hurdle is achieved.

Industry Context

This filing reflects a routine executive compensation event, where performance-based equity awards vest upon meeting specific company performance targets. This is a common practice in the pharmaceutical industry to align executive incentives with shareholder value and retain key talent.

Comparison to Industry Standards

• The use of performance stock units (PSUs) tied to stock price hurdles is a standard executive compensation mechanism across the biotechnology and pharmaceutical sectors.
• This structure is similar to practices observed at major pharmaceutical companies such as Pfizer, Merck, or Amgen, where long-term incentives are designed to reward sustained share price appreciation and executive retention.
• While the specific hurdle details are not disclosed, preventing a direct comparison of the difficulty of achievement, the overall compensation structure is typical for an executive at this level within the industry.

Stakeholder Impact

• Shareholders: The vesting of performance stock units indicates the achievement of a stock price hurdle, which could be viewed positively as it suggests company performance met a pre-defined target.
• Employees (specifically Steven L. Basta): The vesting represents a realization of compensation tied to company performance, reinforcing executive alignment with shareholder interests.

Next Steps

• Remaining 270,000 performance stock units will vest based on future stock price hurdles over four years, subject to Steven L. Basta's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance stock units and subsequent tax withholding. While the vesting indicates the achievement of a stock price hurdle, which is a positive sign of company performance, the transaction itself is not indicative of new strategic developments or significant changes in the company's fundamental outlook. It does not provide sufficient new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Phathom Pharmaceuticals, PHAT, Steven L. Basta, Form 4, Insider Transaction, Performance Stock Units, PSU Vesting, Stock Price Hurdle, Executive Compensation, Tax Withholding